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Abstract
In the era of personalized medicine, head and neck squamous cell carcinoma (HNSCC) represents a critical oncologic
topic. Conventional chemotherapy regimens consist of drugs administration in cycles near or at the maximum tolerated
dose (MDT), followed by a long drug-free period to permit the patient to recover from acute toxicities. Despite
this strategy is successful in controlling the cancer process at the beginning, a significant number of HNSCC
patients tend to recurred or progress, especially those patients with locally advanced or metastatic disease. The
repertoire of drugs directed against tumor cells has greatly increased and metronomic chemotherapy (MC) could
be an effective treatment option.
It is the purpose of this article to review the concept of MC and describe its potential use in HNSCC. We provide
an update of ongoing progress and current challenges related to this issue.
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Background
In 2015, there will be an estimated 59340 new cases of
head and neck squamous cell carcinoma (HNSCC) in
the United States [1]. Despite advances in surgery (S),
radiotherapy (RT) and chemotherapy (CHT), the sur-
vival of patients with HNSCC has not improved signifi-
cantly over the past decades. The main reason for
treatment failure is the development of loco-regional
recurrences and/or metastasis, especially in patients with
locally advanced disease. Based on Extreme trial results,
platinum-fluorouracil chemotherapy plus cetuximab is
nowadays considered the first-line standard treatment,
due to the significant improvement in median overall
survival (OS) and progression free survival (PFS) com-
pared with CHT alone (10.1 and 5.6 months versus 7.4
and 3.3 months, respectively) [2]. However the response
rate is still low (36 %) [2].
Metronomic chemotherapy (MC) is an emerging thera-
peutic option in clinical oncology and it may prove useful
at least in metastatic HNSCC patients. To develop rational
therapeutic strategies, it is important to identify molecular
targets that are linked to the pathogenesis of HNSCC.
This article provides an overview of MC and the rationale
for investigating whether MC could be considered as a
valid strategy option in the management of HNSCC.
A literature search of Medline database was per-
formed using the following search terms “metronomic
chemothereapy”, “head neck”, “solid tumor” and “con-
tinuous low dose”. English-literature was considered.
Additional references were selected from relevant papers.
There is limited literature regarding MC in HNSCC. To
identify extra data on HNSCC, solid tumor studies were
firstly considered to verify whether it was possible to
extrapolate further relevant information in HNSCC cases.
Moreover a search of the clinical.gov database was con-
ducted to identify ongoing clinical trials. Search strategy
was performed up to May 2015.
The rationale
In recurrent and/or metastatic HNSCC patients, survival
rates are low and several CHT regimens are nowadays
available, after failure of first-line platinum-based regimen,
to improve cancer treatment. Successive lines of CHT
consist of taxanes alone or in combination with cetuxi-
mab, capecitabine and metothrexate, depending on previ-
ously given CHT regimens [3]. The goal is to affect
different molecular targets and cell metabolism pathways.
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Considering the antiangiogenic activity of cytotoxic
agents, MC could be proposed to patients with HNSCC
progression, resistant to other CHT lines or with impaired
general conditions. Taxanes are cytotoxic agents active
against endothelial cells at low-doses; cisplatin blocks spe-
cific steps of angiogenic cascade; methotrexate interferes
with endothelial cell functions without cytotoxic effect [4].
In general, MC increased patient outcomes and showed
clinical benefit (from 30 to 93 %) in other cancer setting,
including advanced breast cancer, recurrent ovarian can-
cer and advanced cancer of various tumor types [5]. The
wide range of response rate seems to be ascribed to the
vast patient heterogeneity. However, both survival and clin-
ical benefits could be theoretically transposed to HNSCC
and deserve further studies. MC could induce tumor re-
sponse in those cases that showed acquired drug resistance
after conventional CHT and its tolerability should compare
favorably with other CHT lines administered [6]. By redu-
cing the time between administrations, the purpose is to
prevent tumor cells regrowth and minimize the possibility
of CHT resistance.
Overview
The term “metronomic” derives from the musical device
“metronome” that produces regular and metrical ticks
that represent a regular aural pulse. In the same way,
MC is the regular administration of CHT that results in
a constant low blood level of the drug. Thus MC does
not refer to the mechanism of action of the antineoplas-
tic drug, but it reflects the frequent administration of
low doses (1/10th–1/3rd of the maximum tolerated dose
[MTD]) of drugs, at shorter intervals without interrup-
tion. It represents a different philosophy from the conven-
tional CHT administration that is based on the MTD, the
highest dose of a treatment with acceptable toxicity able
to kill as many tumor cells as possible.
MC exerts its anti-cancer activity by inhibiting tumor
angiogenesis, stimulating anticancer immune response
and inducing tumor dormancy.
Angiogenesis, the growth of new blood vessels, is asso-
ciated to tumor growth and metastasis. Due to the faster
cell proliferation, as well as the presence of immature
endothelial cells in the basement membrane of new ves-
sel walls and the lack of both innervation and collateral
supply, the vascular endothelium is an attractive vulner-
able element in the tumor [7]. Thus drugs that inhibit
angiogenesis process represent a strategy for stopping
cancer, especially by affecting the regrowth of intratu-
moral vascular endothelial cells. At the beginning, MC
efficacy was exclusively relied on its anti-angiogenesis
mechanism and several angiogenesis inhibitors or anti-
angiogenesis drugs were developed and investigated. The
vascular endothelial growth factor (VEGF) was probably
the most important angiogenesis stimulator and was
believed to play a key role in the neovascularization of
human tumors. It has been suggested that both tumor cells
and their supporting endothelial cells represent the main
target site [8]. The MC antiangiogenic effect was demon-
strated by Browder and Klement in their preclinical studies
of experimental cancer conducted in vitro and in vivo
[6, 9]. Browder et al. showed that cyclophosphamide-
based MC provided sustained apoptosis of endothelial
cells, resulting in eradication of Lewis lung carcinoma
and L1210 leukemia [6]. Klement et al. revealed that
low doses of vinblastine in association with anti-VEGF
resulted in full regressions of large established tumors,
without increasing toxicity [9].
MC induced also important immunomodulatory effects.
The activation of both innate and adaptive immune
system is mediated by some drugs, including taxanes and
cyclophosphamide. It has been demonstrated that MC
selectively induced reduction of circulating regulatory T
cells and subsequent reduction of their inhibitory func-
tions on antigen-specific immune response [10].
Induction of tumor dormancy is nowadays considered
a potential mechanism of MC. Dormancy is defined as a
pause in cancer progression. There are three mechanisms of
cancer dormancy including angiogenic dormancy (inability
of tumor cells to recruit blood vessels), cellular dormancy
(tumor cells in G0-G1 arrest) and immunosurveillance
(prevent residual tumor cells expansion) [11]. There-
fore, by inhibiting angiogenesis and controlling im-
mune system, MC can promote tumor dormancy.
Preclinical trials
Considering that a considerable percentage of HNSCC
over-express anti-apoptotic Bcl-2 proteins and that high
levels of Bcl-2 correlates with resistance to platinum-
based CHT and thus with a poor prognosis, Bcl-2 path-
way has become an attractive target for investigating the
potential therapeutic effects of new drugs [12, 13]. The
Bcl-2 protein family has four Bcl-2 homology (BH)
domains (BH1, BH2, BH3 and BH4) that are involved in
cellular activities.
Imai et al. have demonstrated that MC, based on
BH3-mimetic drug (AT101), in association with taxotere
decreased both tumor mitotic index and microvessel dens-
ity and increased survival of mice bearing HNSCC xeno-
grafts [14]. Authors evaluated the combination AT101/
taxotere on the survival of endothelial cells and HNSCC
also in vitro. They observed an additive toxicity for endo-
thelial cells and a synergistic toxicity for tumor cells.
Authors concluded that, based on these results, HNSCC
patients might benefit from this MC regimen.
Same conclusions were proposed by Zeitlin et al. [15].
They investigated the effect of metronomic TW-37, an in-
hibitor drug that occupies the BH3 domain, in combination
with RT in vitro and in xenograft models of HNSCC.
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The study showed that MC potentiates the RT anti-
tumor effects.
Clinical trials
The number of clinical trials of MC in HNSCC is still
very limited, but results are promising (Table 1).
Patil et al. [16] believe that oral MC may be safer and
more effective in patients with metastatic, relapsed or
inoperable HNSCC. In a phase II trial, they randomized
a total of 110 patients to oral MC (57 patients; daily cel-
ecoxib 200 mg × 2 and weekly methotrexate 15 mg/m2)
versus platinum-based CHT (53 patients; cisplatinum
75 mg/m2 given 3 weekly). Overall survival, as well as
progression free survival were significantly increased in
MC patients compared to CHT arm (101 versus 66 days,
p = 0.014 and 249 versus 152 days, p = 0.02, respectively).
One limit of this trial is that the control group utilized
only cisplatinum, which may have resulted in a worst
outcome. Authors motivate this protocol due to cetuxi-
mab financial constrains.
Pai et al. [17] described their experience with MC in
32 locally advanced oral cancer patients, having a wait-
ing period for surgery > 3 weeks. It was a retrospective
chart analysis and MC was started while patients were
awaiting surgery and continued during the perioperative
period and after the adjuvant therapy. MC consisted of
oral methotrexate 15 mg/m2 once a week and oral cele-
coxib 200 mg twice daily. Outcomes of these patients
were compared with 32 stage-matched controls with
similar waiting periods. In those patients who received
at least 3 months of MC in the adjuvant setting, the 2-year
DFS showed a statistically significant improvement com-
pared to the control group (94.6 % vs 75.4 %, p-value 0.03).
Recently in conjunction with the 2015 ASCO Annual
Meeting, Mateen et al. [18] have presented their experi-
ence with MC in recurrent HNSCC. A total of 72
patients were enrolled and were prescribed oral metho-
trexate 2.5 mg twice in a week and capecitabine 500 mg
twice a day, for at least 6 months. Two-year progression-
free survival and overall survival were 18 and 40 %
respectively. Based on these results, authors concluded
that MC is a valid option treatment in this setting of pa-
tients. Otherwise full text paper is still not available, thus
results are not definitive.
To our knowledge, at present, no more published
clinical trials on MC in HNSCC population are available.
Consequently we have tried to collect HNSCC data from
studies that have analyzed MC in solid tumors.
In a multicentre randomized phase II trial, Penel et al.
have evaluated the safety and the efficacy of MC versus
megesterol acetate in 88 patients (of whom 8 HNSCC
cases) with progressive disease [19]. Eligible patients had a
good PS and had exhausted all validated therapies under
standard care. Results were favorable as reflected from the
median overall survival (195 days versus 144 days in the
MC arm and magestrol acetate arm, respectively).
Briasoulis et al. enrolled 62 patients with advanced
refractory cancer to obtain preliminary data on efficacy
of MC vinorelbine [20]. Of the entire cohort, only one
HNSCC patient was recorded. Clinical response was
documented in 8 patients and 32 % of patients experi-
enced disease stability for minimum 6 months.
But, both studies suffered from patients heterogeneity
and insufficient details of HNSCC patients, and there-
fore cannot provide additional support for the imple-
mentation of MC in HNSCC treatment.
Ongoing trials
There are two ongoing clinical research studies testing
MC in head and neck cancer (https://clinicaltrials.gov).
The “Metronomic Chemotherapy With Tegafur/Uracil
for Patients With Locally Advanced (Stage III ~ IVB)
Head and Neck Squamous Cell Carcinoma (HNSCC)”
(ClinicalTrials.gov Identifier: NCT00855881) is a trial
conducted at the Mackay Memorial Hospital, Taipei,
Taiwan. It is a phase II trial in which patients with
histologically confirmed non-nasopharyngeal HNSCC
are treated with tegafur-uracil, an oral fluoropyrimidine
prodrug, for 1 year after complete response to previous
treatment. Primary outcome is to evaluate the 2-year
relapse free survival. This study is currently recruiting
participants and preliminary results on primary outcome
measures are still not available.
The Masonic Cancer Center, University of Minnesota has
proposed a phase II study (ClinicalTrials.gov Identifier:
NCT01581970) to assess the effectiveness of weekly cetuxi-
mab associated with twice daily low dose oral cyclophos-
phamide for 12 weeks, in patients with metastatic HNSCC
who have progressed on first line CHT. Primary outcome
Table 1 Metronomic chemotherapy clinical trials in HNSCC patients
Author Year Study design Patients (n) Protocol (n patients) Results
Patil et al. [16] 2015 phase II 110 celecoxib +methotrexate (57); cisplatinum (53) OS 101 vs 66 days*; PFS 249 vs 152 days*
Pai et al. [17] 2013 retrospective 64 celecoxib +methotrexate (32); no MC (32) 2-year DFS 94.6 % vs 75.4 %*
Penel et al. [18] 2010 randomised 88 cyclophosphamide (44); megestrol acetate (44) 2-month PFS 20.5 % vs 9 %; median OS 195 vs
144 days
n number, OS overall survival, PFS progression free survival, MC metronomic chemotherapy, DFS disease free survival
*: p-value < 0.05
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measure is progression free survival at 2 years. This study is
ongoing, but not recruiting participants.
Consideration
Despite literature data are still restricted and thus defini-
tive consideration cannot be drawn, all clinical trials dem-
onstrated that MC is a well-tolerated treatment. Severe
toxicity was not reported. The full impact of MC on
tumorogenesis and prognosis has yet to be realized. The
potentiality of MC as RT or CHT sensitizer is still
unknown, but its anticancer effect, as well as its lower
toxicity profile, can suggest a role in both palliative and
consolidation approaches.
When a treatment strategy can yield a good tumor
control with a low toxic profile, other determinants
should be taken into account in selecting patient sub-
sets, including both patient (quality of life, preference
and convenience) and research profile (resource cost,
rationale and end-points). Thus MC should represent a
convenient opportunity in poor PS or terminal stage
patients to improve their quality of life by decreasing
pain and maintaining daily function, and, in the same
time, to control metastatic disease.
On the other hand, although without a strong scien-
tific basis, MC should be considered a valuable option,
especially in those patients with a good PS that are
reluctant to accept exclusive palliative care [19]. Several
preclinical studies and a few small clinical trials have
recently reported encouraging results in adjuvant setting.
Which is the most effective MC regimen is still difficult
to conclude. In Japan and in several other Asiatic coun-
tries, MC with Tegafur/Uracil is the first choice, based
on empiric data and on the efficacy demonstrated in
adjuvant setting for locally advanced stage HNSCC
patients [21–23]. Lam et al. reported the first prospect-
ive randomized trial in which a trend of better control
of distant metastasis was observed in the adjuvant MC
group (10 % versus 32 % for the control group) [21].
Nevertheless, there is no unanimous consensus for the
use of one MC regimen over the other, due to the small
study populations. Literature data suggested that MC
treatment strategy is promising in the treatment of
HNSCC, but a large-scale randomized trial should be
paramount to test the optimal regimen to be used.
Overall, MC has not been yet tested for treatment in
combination with RT and it could provide significant
clinical benefit and improve quality of life in recurrent
or metastatic HNSCC. The effects could be improved by
concurrent administration of RT that inhibits the pro-
cesses of growth and tumor formation. The rationale
behind the use of MC is to reduce adverse drug reac-
tions and to target both endothelial cells and tumor cells
which are at proliferating stage [24]. MC and RT could
have a synergic effect: to suppress more effectively the
proliferating endothelial cells in the tumor area, and, on the
other hand, to facilitate tumor cells damage by radiation-
induced cell death.
Conclusion
There is still much to be learned in this field, especially
with regard to optimization of the proper drugs, dose,
schedule, and tumor applications. We hypothesized that
MC could have a role in HNSCC treatment and may be
best combined to CHT and RT to improve antiangio-
genic and anticancer efficacy. Surely, further studies are
needed before MC can be successfully integrated into
HNSCC clinical practice.
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